BioInvents BI-1206 to advance into expansion stage of phase 1/2a study in NHL after productive end-of-phase 1 US FDA meeting

BioInvent International AB (BioInvent), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces its novel anti-FcyRIIB antibody BI-1206 is progressing into the expansion phase of a phase 1/2a trial for non-Hodgkin